报价延迟最少15分钟:2025/07/23 04:30 EDT
盘前时段
|
||||
|
-- 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
22.57
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.37/1.13
|
|
企业价值
3.77B
|
| 资产负债 |
|
每股账面净值
4.57
|
| 现金流量 |
|
现金流量率
0.04
|
| 损益表 |
|
收益
957.80M
|
|
每股收益
3.78
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/23 04:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc. |
